Phase I/II study of triweekly administration regimen of irinotecan and TS-1 in patients with advanced colorectal cancer

ABSTRACT: Interventions: Treatment : TS-1+CPT-11 Primary outcome(s): 1) Phase I To determine the recommended dose 2) Phase II Response Rate Study Design: Single arm Non-randomized

DISEASE(S): Advanced Colorectal Cancer

PROVIDER: 2616857 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR